

**Zakaria Abd Elmageed, MS, PhD, FIPE**  
Associate Professor of Pharmacology

**Office Address**            Edward Via College of Osteopathic Medicine  
Biomedical Science, Discipline of Pharmacology  
4408 Bon Aire Drive  
Monroe, LA 71203

**Phone:**                    Office: (318) 342-7185

**Email:**                    [zelmageed@ulm.vcom.edu](mailto:zelmageed@ulm.vcom.edu)

## EDUCATION AND TRAINING

- Postdoctoral training, Department of Urology, Tulane University School of Medicine, LA, USA, 2009 to 2011
- Postdoctoral training, Division of Endocrinology, Johns Hopkins School of Medicine, MD, USA, 2009
- Postdoctoral training, Department of Pathology, LSU Health Sciences Center, School of Medicine, LA, USA, 2006-2008
- Ph.D. Degree in Biology and Biochemistry, Helwan University, 2004
- Master of Science in Physiology, Helwan University, 1999
- Bachelor of Science with Honor, Cairo University, 1995

## PERSONAL STATEMENT

### Teaching

- Coming with more than 16-year of teaching experience, I have taught pharmaceutical and biomedical sciences for graduate and postgraduate students including medical and Pharm-D students in multiple disciplines. I have taught Pharmacology, Human Physiology, Biochemistry, Oncology, Genomics & Transplant, Cell Signaling & Therapeutics, and Molecular Biology courses.
- Inaugural Fellow in Interprofessional Education (FIPE), Texas A&M University, TX, 2019

### Research

- I have published over 80 articles in *peer-reviewed* journals of basic and translational sciences in addition to 77 conference presentations and published abstracts. The impact of my research is highly sounded as reported by Google Scholar (**H-index:** 32, **citations:** 3014) and ResearchGate score 42.25 (Score is higher than 97.5% of affiliated members)
- Active member in several scientific associations and served as *ad hoc* reviewer in a number of *peer-reviewed* journals. I have mentored over 32 PhD students, postdocs, OMS and MD Fellows in the field of cancer signaling, biomarkers and pharmacology, and managed large-scale trainees as well as overseeing many research projects.
- During my research training, I had a very good opportunity to join a remarkable cancer research team, which was focusing on the crosstalk between patients' adipose-derived stem cells and prostate cancer progression. Our findings anticipated that the release of exosomes rewires the steroidal hormone receptor signaling such as androgen receptor (AR) and estrogen receptors (ERs) in the nucleus of the stem cells, which contributes to tumor progression.
- One of my research interests is spanning around the diagnostic/prognostic utilities of exosomal cargos as biomarkers and their role in altering the tumor microenvironment for promoting tumor progression and metastasis.

## **LEADERSHIP POSITIONS**

- 2019-2020 Lead Faculty of College Strategic Plan for 2025: College of Pharmacy, Texas A&M University  
2019 Interprofessional Education Faculty Fellow of Health Science Center, Texas A&M University  
2017-2020 Senator (elected), Texas A&M University Senate, College Station, Texas  
2017-2019 Caucus Leader, Rangel College of Pharmacy, Texas A&M University, College Station, Texas  
2015-2016 Director of Oncology Research, Department of Surgery and ENT, Tulane University School of Medicine, New Orleans, LA.  
2015-2016 Director of Translational Research Development, Department of Otolaryngology, Tulane University School of Medicine, New Orleans, LA.

## **PROFESSIONAL APPOINTMENTS**

- 2020 to date Associate Professor of Pharmacology, Edward Via College of Osteopathic Medicine (VCOM-LA), University of Louisiana Monroe, LA, USA  
2016-2020 Assistant Professor-Tenure-Track, Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Science Center, College Station/Kingsville, TX, USA  
2015-2016 Assistant Professor-Research Track, Departments of Surgery and Otolaryngology, Tulane University School of Medicine, New Orleans, LA, USA  
2015-2016 Member, Tulane Biomedical Sciences (BMS) graduate program, Tulane University.  
2014-2016 Director of Oncology Research, Surgery and Otolaryngology, Tulane University School of Medicine, New Orleans, LA, USA  
2014-2015 Research Scientist, Departments of Surgery and Otolaryngology, Tulane University School of Medicine, New Orleans, LA, USA  
2012-current Member, Tulane Cancer Center, Cell Signaling Program, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA  
2012-2014 Instructor of Urology, Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA

## **ACADEMIC COMMITTEES**

- 2022 Member of the VCOM Wellness Committee, Edward Via College of Osteopathic Medicine (VCOM), Monroe, LA  
2020 Member of the Professional and Ethical Standard Board Committee, Edward Via College of Osteopathic Medicine (VCOM), Monroe, LA  
2019 Member of College Search Committee for the head of the department of pharmaceutical Sciences, College of Pharmacy, Texas A&M University  
2019 Lead Faculty of Strategic Priorities Committee for Resources, College of Pharmacy, Texas A&M  
2019-2020 Committee of Interprofessional Education for Palliative Care, Health Science Center, Texas A&M  
2019-2020 TAM Wellness Committee, Texas A&M University, College Station, TX  
2018-2019 Texas A&M Research Committee, Texas A&M University, College Station, TX  
2017-2018 Texas A&M Planning Committee, Texas A&M University, College Station, TX  
2017-2019 Caucus Leader, Rangel College of Pharmacy, Texas A&M University, College Station, TX

2017-2020	Faculty Development Committee, Rangel College of Pharmacy, Texas A&M Health Science Center, College Station/Kingsville, TX
2018-2020	Member of the Admission's Committee, Rangel College of Pharmacy, Texas
2018-2020	Member of the <i>Ad hoc</i> Diversity Leadership Council, Rangel College of Pharmacy, Texas
2015-2016	Director of Oncology Research, Department of Surgery and ENT, Tulane University School of Medicine, New Orleans, LA.
2015-2016	Director of Translational Research Development, Department of Otolaryngology, Tulane University School of Medicine, New Orleans, LA.
2005-2006	Senate member, University Committee for Postgraduate Studies and Research Development, Helwan University (Only two faculty members were selected from each College).
2004-2006	Member, Faculty Committee for Chemical and Instruments Supply, Helwan University
2004-2006	Member, Faculty of Science Council for Undergraduate Student Affairs and Technical University Official Support (TUOS), Helwan University

## GRANTS

### Active

- **Delta Collaborative Research Program (ULM/VCOM). Project# 22-0016-A0001.** Title: Oleocanthal as a novel SMYD2 modulator for the control of prostate cancer. Abd Elmageed ZY (**PI: VCOM**), and El Sayed K (**PI: ULM**).  
Funding period: 07/01/2022-06/30/2022.
- **VCOM REAP. Project# 22-0015-A0001.** Title: Small extracellular vesicles-stromal interaction promotes aggressive phenotypes in prostate cancer cells. **PI:** Abd Elmageed ZY  
Funding period: 07/01/2022-06/30/2022.
- **VCOM REAP. Project# 22-0031-A0001.** Title: Confirming immunosuppressive mutations in clonal hematopoietic (CH) tumor infiltrating immunocytes (TII) in lung adenocarcinoma (LUAD). **PI:** Anandakrishnan and **Co-I:** Abd Elmageed ZY  
Funding period: 07/01/2022-06/30/2022.

### Completed

- **Delta Collaborative Research program (ULM/VCOM).** Title: CSK9 axis: Novel molecular target and inhibitor for metastatic castration-resistant prostate cancer recurrence. Abd Elmageed ZY (**PI: VCOM**), and El Sayed K (**PI: ULM**).  
Funding period: 07/01/2021-06/30/2022.  
*Goals:* To determine the efficacy and molecular target selectivity for the small molecule PCSK9 axis targeting molecule pseurotin A (PS) in a nude mouse model for mCRPC recurrence.
- **Texas A&M University T3 grants.** Title: Exosomes as a mechanistic model for development of drug resistance in prostate cancer patients.  
**PI:** Abd-Elmageed ZY. Funding period: 08/01/2018-07/30/2020.
- **Texas A&M Health Science Center, Rangel College of Pharmacy Startup fund.** Title: Molecular studies on prostate cancer progression and metastasis.  
**PI:** Abd-Elmageed ZY. Funding period: 10/01/2016-07/31/2020.
- **Discovery Foundation:** Title: New Insights into the role of Transmembrane and Tetratricopeptide Repeat Containing 4 (TMTTC4) as a potential marker and therapeutic target in breast cancer.

**PI:** Abd-Elmageed ZY. Funding period: 07/01/2018-06/30/2019.

- **NIH R21CA194750.** The role of exRNA in health disparity of prostate cancer. **PI:** Abd-Elmageed ZY. Funding period: 2 years. 07/01/2015-06/30/2018. *Total budget: \$419,000.00*  
*The objective for this study is to elucidate the pro-oncogenic activity of exosomes-associated microRNAs and their clinical use as a surrogate in health disparity of prostate cancer.*
- **National Center for Advancing Translational Sciences (NCATS), NIH.** 1UH2TR000928-01. Title: Targeting tumor-derived exRNA-containing microvesicles by high throughput screening. Abdel-Mageed AB (PI), and **Abd Elmageed ZY (Co-I).** Funding period: 4 years. 09/01/2013-08/31/2016. Total budget: \$4,200,000  
*The goal was to elucidate the mechanism of exosomes release and uptake and screening of FDA-approved therapeutic inhibitors for specific targeting exosomes of tumor cells using High throughput techniques*
- **Louisiana Clinical & Translational Science Center (LaCaTS) Pilot Grant Round I.** Title: Discovering the Role of Putative MicroRNAs in Prostate Tumorigenesis. **PI:** Abd-Elmageed ZY. Funding period: 03/29/2013 to 04/28/2014. *This study focused on discovering the role of new identified upregulated microRNAs in the exosomes released from prostate cancer cells and investigating their contribution to tumorigenesis of prostate cancer.*

## PATENTS

- *In vitro* and *in vivo* Tetracycline inducible fluorescently-tagged protein expression system. Inventor: A Ouhitit (PI), **Abd Elmageed, ZY (Co-PI)**, M Zerfauoi (Co-PI). Invention serial number: 60/956,437. LSU Health Sciences Center, LA, 2010.

## HONORS AND AWARDS

- 2019 Inaugural Fellow of Interprofessional Education (FIPE) of Texas A&M Health Science Center. A national program to advance interprofessional education in palliative care, Texas A&M University, College Station, Texas
- 2019 Certificate of Participation of completed the NIH-sponsored Interactive mentoring to enhance research skills (IMERS) grant-writing workshop held on the University of Kentucky on October 28-30, 2019
- 2019 Certificate of Appreciation by the AACR for participation in the Clinical Cancer Research manuscript review activity
- 2018 Certificate of Appreciation by the journal of "Scientific Reports" for serving on the Editorial Board of the journal
- 2018 Certificate of Appreciation by the 2018 Emperor Science Award Program Mentor. Stand Up To Cancer, PBS Learning Media, USA
- 2017 American Association for Cancer Research (AACR) Scholar-in-Training Award to Dr. Hamdy Ali (Postdoctoral Fellow from my Team). Title: Exosomes-associated miR-3128 and miR-3613 are dysregulated in African American men with prostate cancer and correlated with poor prognosis. The Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic minorities and the Medically Underserved, Atlanta, GA
- 2016 Scientific Judge in the AACR Career Development and Mentoring Committee during the Eleventh Annual AACR Undergraduate Student Caucus and Poster Competition. April 16, 2016, New Orleans, LA
- 2016 Oral presentation in The American Association of Endocrine Surgeons. Baltimore, MD. April 09-12, 2016. Title: Synergistic effects of BRAF and proteasome inhibitors for treating aggressive thyroid cancer. Tsumagari K, **Abd Elmageed Z. et. al.**
- 2015 R21 NCI/NIH Award. Title: The role of exRNA in health disparity of prostate cancer (PI: **Abd-Elmageed ZY**)

- 2013 Louisiana Clinical & Translational Science Center (LaCaTS) for translational research (PI: **Abd-Elmageed ZY**). Title: Discovering the role of putative microRNAs in prostate tumorigenesis.
- 2013 National Center for Advancing Translational Sciences (NCATS) Award (\$4.2 million grant). Abdel-Mageed AB (PI), Mondal D (Co-I) and **Abd Elmageed ZY** (Co-I).
- 2013 Oral Presentation in Academic Surgical Congress, February 4-7th. Title: Simultaneous suppression of the MAP kinase and PI3K/Akt pathways in aggressive thyroid cancer. Li X, **Abd Elmageed ZY**, Kandil E.
- 2013 Oral Presentation in Academic Surgical Congress, February 4-7th. Title: CD146-Latexin crosstalk and their potential role in thyroid tumorigenesis. **Abd Elmageed ZY** et al.
- 2013 One of the top 10 abstracts at the 19th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America. The award resulted in an oral presentation. See Invited Talks. Oral presentation and Title: Early combined treatment with Avanafil and adipose tissue-derived stem cells promotes recovery of erectile function in a rat model of postprostatectomy induced erectile dysfunction. Gokce A, **Abd Elmageed ZY**, et al.
- 2011 First place Award during poster presentation of American Association of Head and Neck Surgery, Chicago, IL
- 2006 Fellowship Award for Postdoctoral training, Ministry of Higher Education, Egypt
- 2005 Teaching Award, Best Teacher of the Year, Faculty of Science, Helwan University

## PROFESSIONAL AFFILIATIONS

- 2019-current American Colleges of Clinical Pharmacology (ACCP)
- 2019-current American Association of Pharmaceutical Sciences (AAPS)
- 2017-current American Association of Colleges of Pharmacy (AACP)
- 2010-current American Association for Cancer Research (AACR)
- 2009-2016 American Association for the Advancement of Science (AAAS)
- 2008-2011 American Heart Association (AHA)
- 2008-2011 American Physiological Society (APS)

## EDITORIAL BOARDS AND JOURNAL REVIEWER

### **Editorial Board Member and Guest Editor**

1. *Scientific Reports, Nature Publisher*
2. *Guest Editor in Cancers*
3. *Cancer Health Disparity*
4. *Board Reviewer in TME of Frontiers in Oncology*

### **Ad Hoc Reviewer** in the following journals:

1. *Clinical Cancer Research*
2. *Cancer Research*
3. *Cancers*
4. *BMC Genomics*
5. *Journal of Pineal research*
6. *Epigenetics*
7. *Oncotarget*
8. *Molecular Carcinogenesis*
9. *PLOS One*

10. *Tumor Biology*
11. *Cancer Biology and Therapy*
12. *Andrology*
13. *Digestive Diseases and Sciences*
14. *Oxidative Medicine and Cellular Longevity*
15. *Integrative Biology*
16. *Molecular Biosystems*
17. *Metallomics*
18. *World J. Surgical Research*
19. *Biomaterials Science*
20. *Clinical and Experimental Pharmacology and Physiology*
21. *World Journal of Gastroenterology*
22. *J. Nanoparticle Research*
23. Mediators of inflammation

## INVITED SPEAKER

- 2022 Speaker in the 1<sup>st</sup> International Conference on Pharmaceutical and Bio-Medical Research (PBMR2022). Title: **New insights into the role of nuclear BRAF in promoting tumor aggressiveness and drug resistance.** Saini University. March 20<sup>th</sup> - 21<sup>st</sup>, 2022.
- 2021 2021 VCOM Research Retreat. The Westin Hilton Head Island resort & SPA. **Tiny bodies with multiple functions: The role of exosomes in promoting prostate cancer.** Dec. 3-5, 2021
- 2020 Speaker in Drug Development Congress 2020. Title: **Targeting exosomal uptake by methyl- $\beta$ -cyclodextrin inhibits exosomal transfer of ITG2A and decreases the aggressive behavior of prostate cancer cells.** 2nd International Conference on Drug Discovery and Drug Development (Virtual). Zurich, Switzerland, October 21-22, 2020.
- 2019 Speaker in the seminar series held in the Department of Immunology and Microbiology, College of Medicine, University of Texas (UTRGV). **The hidden-wolf among the lambs: Clinical and therapeutic implications of mutant BRAF in melanoma patients.** December 14, 2019.
- 2019 Guest Speaker in the Department of Surgery "Division of Endocrine Surgery", School of Medicine, Tulane University, New Orleans, LA. **Suppression of CDC7 sensitizes resistance melanoma cells to BRAF-V600E inhibitor by targeting CDC7/MCM2-7 pathway.** February 25, 2019.
- 2017 Speaker in the Department of Cell and Molecular Biology, College of Medicine, College Station. Texas A&M Health Science Center. **New insights into the role of Exosomes in prostate cancer progression** April 20, 2017.
- 2016 Speaker in the Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Science Center. **Patients Derived Adipose Stem Cells Promote Prostate Cancer Progression through Exosomes-Associated Mechanisms.** April 27, 2016.
- 2013 Oral presentation entitled: **Early combined treatment with Avanafil and adipose tissue-derived stem cells promotes recovery of erectile function in a rat model of post prostatectomy induced erectile dysfunction.** Gokce A, Abd Elmageed ZY, et al.
- 2013 Oral Presentation in Academic Surgical Congress, February 4-7th. Title: CD146-Latexin crosstalk and their potential role in thyroid tumorigenesis. *Abd Elmageed ZY et al.*
- 2013 Oral Presentation in Academic Surgical Congress, February 4-7th. Title: **Simultaneous suppression of the MAP kinase and PI3K/Akt pathways in aggressive thyroid cancer.** Li X, *Abd Elmageed ZY, Kandil E.*
- 2012 Tulane University School of Medicine, New Orleans, LA. **The cross-talk between adipose stem cells and prostate cancer: Is that a Friend or a Foe?** Summer Research Day

- 2011 Tulane University School of Medicine, New Orleans, LA. **Estrogen-ER $\beta$  Axis in the Progression of Prostate Cancer**. Summer Research Day
- 2010 Department of Urology, Tulane University School of Medicine, New Orleans, LA. **Patient Derived Adipose Stem Cells and Prostate Cancer Progression**
- 2007 Louisiana Cancer Research Center (LCRC) for Breast/Ovarian Cancer Group Series, LSU Health Science Center & Tulane Cancer Centre, New Orleans, LA. **The role of Cell Adhesion Molecule CD146 in suppressing breast tumor progression**
- 2007 Stanley S. Scott Cancer Centre Seminar Series, LSU Health Science Center, New Orleans, LA. **Early dysfunction of the p16/Rb pathway and identification of novel p16-target genes associated with UV-induced melanoma**
- 2006 Pathology Department Seminar Series, LSU Health Science Center at New Orleans, LA. **Dysregulation of p16INK4a and its role in the development of melanoma**
- 2005 SIRA Institute for Molecular Biology, Cairo, in collaboration with the University of Florida. **Concepts of Molecular Biology Techniques in Cancer Therapy**

### TEACHING EXPERIENCE

- 2020 to date Pharmacology course for the first- and second-year medical students (blocks 2-8), Discipline of Pharmacology, Biomedical Sciences, Edward Via College of Osteopathic Medicine, ULM, Monroe
- 2017 - 2020 Course coordinator and instructor of Oncology (IPT VIII PHAR 813) course for the third-year Pharmacy students, 3 credit hours. Rangel College of Pharmacy, Texas A&M University, TX.
- 2016 - 2020 Human Physiology course (PHAR 626) for the first-year Pharmacy students P1, 4 credit hours Rangel College of Pharmacy, Texas A&M University, TX.
- 2019-2020 Biochemistry course (PHAR 627) for the first-year Pharmacy students P1, 4 credit hours Rangel College of Pharmacy, Texas A&M University, TX.
- 2014-2016 Participating in teaching graduate students Cell Signaling course (3 credit hours), Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, LA
- 2015-2016 Human Anatomy and Physiology (Biol-161, 3 credit hours) and human Biology (Biol-141, 3 credit hours), Department of Science and Math, Delgado, New Orleans, LA
- 2009-2014 Pharmacology and Molecular biology of cancer disease, graduate students and laboratory fellows at Tulane University School of Medicine, New Orleans, LA
- 2006-2008 Molecular biology for medical students, School of Medicine, LSU Health Sciences center
- 2004-2006 Radiation Biology and Toxicology, Faculty of Science, Helwan University
- 2004-2006 Cell Biology, Medical parasitology and immunology, Faculty of Science, Helwan University
- 2004-2006 Physiology, Faculty of Science, Helwan University, Cairo.
- 2000-2004 Teaching Instructor, Faculty of Science, Helwan University, Cairo.
- 1996-1999 Teaching Assistant, Faculty of Science, Helwan University, Cairo.

### MENTORING AND SUPERVISORY ROLE (32 Trainees)

Over the last several years, I have trained MD, DO, Postdocs and PhD candidates in different disciplines including urology, pharmacology and oncology in three institutes (Texas A&M University, Tulane School of Medicine and VCOM). I mentored 3 postdocs, 9 PhDs, 9 MDs, 4 Pharm-Ds and 7 OMS I-III. A number of these fellows pursuing

their professional career in Harvard, Johns Hopkins, The University of Chicago, Texas A&M, Baylor and Rutgers.

**PUBLICATIONS, 80 peer-reviewed publications (H-index: 32, citations: 3014, Google scholar: Updated on August 02, 2022)**

1. El-Daly SM, Gouhar SA, **Abd Elmageed ZY**. Circulating microRNAs as reliable tumor biomarkers: Opportunities and Challenges facing Clinical Application. *J Pharmacol Exp Ther*. 2022 Jul 9; JPET-MR-2021-000896.
2. Siddique AB, Ebrahim HY, Tajmim A, King JA, Abdelwahed KS, **Abd Elmageed ZY**, El Sayed KA. Oleocanthal Attenuates Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence by Targeting SMYD2. *Cancers* 2022, 14(14), 3542.
3. Zerfaoui M, Tsumagari K, Toraih E, Errami Y, Ruiz E, Elaasar MSM, Krzysztof M, Sholl AB, Magdeldin S, Soudy M, **Abd Elmageed ZY**, Boulares Ah, Kandil E. Nuclear interaction of Arp2/3 complex and BRAFV600E promotes aggressive behavior and vemurafenib resistance of thyroid cancer. *Am J Cancer Res* 2022;12(7): 3014-3033.
4. Ahmed EY, Abdelhafez OM, Zaafar D, Serry AM, Ahmed YH, El-Telbany RFA, **Abd Elmageed ZY**, Ali HI. Antitumor and multikinase inhibition activities of some synthesized coumarin and benzofuran derivatives. *Arch Pharm* (Weinheim). 2022 Mar 14:e2100327.
5. Malkaram SA, Shatnawi A, Fan J, Carraway H, Denvir J, Primerano DA, **Abd Elmageed ZY**, Fandy TE. Differential histone posttranslational modifications induced by DNA hypomethylating agents. *Cancer Control*. 2022; 29:10732748221074051.
6. Al Omairi NE, Albrakati A, Alsharif KF, Almalki AS, Alsanie W, **Abd Elmageed ZY**, Zaafar D, Lokman MS, Bauomy AA, Belal SK, Abdel-Daim MM, Abdel Moneim AE, Alyami H, Kassab RB. Selenium Nanoparticles with prodigiosin rescue hippocampal damage associated with epileptic seizures induced by pentylene tetrazole in rats. *Biology* (Basel). 2022 Feb 23;11(3):354.
7. Zerfaoui M, Toraih E, Ruiz E, Errami Y, Attia AS, Krzysztof M, **Abd Elmageed ZY**, Kandil E. Nuclear Localization of BRAFV600E Is Associated with HMOX-1 Upregulation and Aggressive Behavior of Melanoma Cells. *Cancers* (Basel). 2022 Jan 9;14(2):311.
8. Albrakati A, Alsharif KF, Al Omairi NE, Alsanie WF, Almalki ASA, **Abd Elmageed ZY**, Elshopakey GE, Lokman MS, Bauomy AA, Abdel Moneim AE, Kassab RB. Neuroprotective Efficiency of Prodigiosins Conjugated with Selenium Nanoparticles in Rats Exposed to Chronic Unpredictable Mild Stress is Mediated Through Antioxidative, Anti-Inflammatory, Anti-Apoptotic, and Neuromodulatory Activities. *Int J Nanomedicine*. 2021 Dec 30; 16: 8447-8464.
9. Ali HEA, Gaballah MSA, Gaballa R, Mahgoub S, Hassan ZA, Toraih EA, Drake BF, **Abd Elmageed ZY**. Small Extracellular Vesicle-Derived microRNAs Stratify Prostate Cancer Patients According to Gleason Score, Race and Associate with Survival of African American and Caucasian Men. *Cancers (Basel)*. 2021 Oct 19; 13(20): 5236.
10. Abdelwahed K, Siddique A, Qusa MH, King JA, Souid S, **Abd Elmageed ZY**, El Sayed KA. PCSK9 Axis-Targeting Pseurotin A as a Novel Prostate Cancer Recurrence Suppressor Lead. *ACS Pharmacol Transl Sci*. 2021 Oct 5;4(6):1771-1781.
11. Makboul R, Abdelkawi IF, Badary DM, Hussein MRA, Rhim JS, Toraih EA, Zerfaoui M, **Abd Elmageed ZY**. Transmembrane and Tetratricopeptide Repeat Containing 4 Is a Novel Diagnostic Marker for Prostate Cancer with High Specificity and Sensitivity. *Cells*. 2021 Apr 27;10(5):1029.
12. Zerfaoui M, Dokunmu TM, Toraih EA, Rezk BM, **Abd Elmageed ZY**, Kandil E. New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking. *Cells*. 2021 Feb 10;10(2):367.
13. Elwaie TA, Abbas SE, Aly EI, George RF, Ali H, Kraiouchkine N, Abdelwahed KS, Fandy TE, El Sayed KA, **Abd Elmageed ZY\***, Ali HI. HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability. *J Med Chem*. 2020 Dec 14. doi: 10.1021/acs.jmedchem.0c01647. PMID: 33314925

14. Gaballa R, Ali HEA, Mahmoud MO, Rhim JS, Ali HI, Salem HF, Saleem K, Kandeil MA, Ambs S, **Abd Elmageed ZY**. Exosomes-Mediated Transfer of ITGA2 Promotes Migration and Invasion of Prostate Cancer Cells by Inducing Epithelial-Mesenchymal Transition. *Cancers (Basel)*. 2020 Aug 15;12(8): E2300.
15. Carraway HE, Malkaram SA, Cen Y, Shatnawi A, Fan J, Ali HEA, **Abd Elmageed ZY**, Buttolph T, Denvir J, Primerano DA, Fandy TE. Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia. *Scientific Reports*. 2020 Jun 25;10(1):10325
16. Saber SH, Ali HEA, Gaballa R, Gaballah M, Ali HI, Zerfaoui M, **Abd Elmageed ZY**. Exosomes are the Driving Force in Preparing the Soil for the Metastatic Seeds: Lessons from the Prostate Cancer. *Cells*. 2020 Feb 28;9(3).
17. Gad S, Ali HEA, Gaballa R, Abdelsalam RM, Zerfaoui M, Ali HI, Salama SH, Kenawy SA, Kandil E, **Abd Elmageed ZY**. Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway. *Scientific Reports*. 2019. 9:14197.
18. Abdelhafez OM, Ahmed EY, Abdel Latif NA, Arafa RK, **Abd Elmageed ZY**, Ali H.I. 2019. Design and molecular modeling of novel P38 $\alpha$  MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds. *Bioorganic & Medicinal Chemistry*. 2019 Apr 1;27(7):1308-1319.
19. Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, Mercer R, van Bokhoven A, Torkko KC, Agarwal C, Agarwal R, **Abd Elmageed ZY**, Yadav H, Mishra SK, Deep G. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. *Cancer Med*. 2019 Mar;8(3):1110-1123.
20. Ali HEA, Emam AA, Zeeneldin AA, Srour R, Tabashy R, El-Desouky ED, **Abd Elmageed ZY**, Abdel-Wahab AA. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. *Clin Biochem*. 2019 Jan 15. pii: S0009-9120(18)30919-6.
21. Ali HEA, Lung PY, Sholl AB, Gad SA, Bustamante JJ, Ali HI, Rhim JS, Deep G, Zhang J, **Abd Elmageed ZY**. Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients. *Sci Rep*. 2018 Nov 5; 8(1):16335.
22. Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, **Abd Elmageed ZY**, Ali HI. Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition. *Eur J Med Chem*. 2018 May 25; 152:31-52.
23. **Abd Elmageed ZY**, Moore RF, Tsumagari K, Lee MM, Sholl AB, Friedlander P, Al-Qurayshi Z, Hassan M, Wang AR, Boulares HA, Kandil E. Prognostic Role of BRAFV600E Cellular Localization in Melanoma. *J Am Coll Surg*. 2018 Apr; 226(4):526-537.
24. Panigrahi GK, Praharaj PP, Peak TC, Long J, Singh R, Rhim JS, **Abd Elmageed ZY**, Deep G. Hypoxia-induced exosome secretion promotes survival of African-American and Caucasian prostate cancer cells. *Sci Rep*. 2018 Mar 1; 8(1):3853.
25. Panigrahi GK, Ramteke A, Birks D, Abouzeid Ali HE, Venkataraman S, Agarwal C, Vibhakar R, Miller LD, Agarwal R, **Abd Elmageed ZY**, Deep G. Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. *Oncotarget*. 2018 Feb 17; 9(17): 13894-13910.
26. Ali HEA, Gad SA, Deep G, Ali HI, **Abd Elmageed ZY**. Health disparity of prostate cancer: Molecular insights into the role of exosomes. *Cancer Health Disparities*. 2017. 1:e1-e13. DOI: 10.9777/chd.2017.10002
27. Ali HEA, Abdel Hameed R, Effat H, Ahmed EK, Atef AA, Sharawi SK, Ali M, **Abd Elmageed ZY**, Abdel Wahab AH. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. *Clin Res Hepatol Gastroenterol*. 2017 Sep;41(4):e51-e62.
28. Tsumagari K, **Abd Elmageed ZY**, Sholl AB, Green EA, Sobti S, Khan AR, Kandil A, Murad F, Friedlander P, Boulares AH, Kandil E. Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. *Endocr Relat Cancer*. 2018 Jan;25(1):99-109.
29. **Abd Elmageed ZY**, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, Boulares H, Friedlander P, Miccoli P, Kandil E. Immunohistochemistry as an Accurate Tool for Evaluating BRAF-V600E Mutation in 130 Samples of Papillary Thyroid Cancer. *Surgery*. 2017 Apr;161(4):1122-1128.

30. Abdel Wahab AH, El-Halawany MS, Emam AA, Elfiky A, **Abd Elmageed ZY**. Identification of circulating protein biomarkers in patients with hepatocellular carcinoma concomitantly infected with chronic hepatitis C virus. *Biomarkers*. 2017 Nov; 22(7):621-628.
31. Gur S, Rezk BM, **Abd Elmageed ZY**, Kadowitz PJ, Sikka SC, Hellstrom WJ. Characterisation of pomegranate juice effects on human corpus cavernosum. *Andrologia*. 2017 Oct;49(8).
32. El-Bahrawy AH, Tarhuni A, Kim H, Subramaniam V, Benslimane I, **Elmageed ZY**, Okpechi SC, Ghonim MA, Hemeida RA, Abo-Yousef AM, El-Sherbiny GA, Abdel-Raheem IT, Kim J, Naura AS, Boulares AH. ApoE deficiency promotes colon inflammation and enhances the inflammatory potential of oxidized-LDL and TNF- $\alpha$  in primary colon epithelial cells. *Biosci Rep*. 2016 Nov 17;36(6).
33. El Jamal SM, Taylor EB, **Abd Elmageed ZY**, Alamodi AA, Selimovic D, Alkhateeb A, Hannig M, Hassan SY, Santourlidis S, Friedlander PL, Haikel Y, Vijaykumar S, Kandil E, Hassan M. Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways. *Cell Div*. 2016 Aug 2; 11:11.
34. Anwar M, Murad F, Dawson E, **Abd Elmageed ZY**, Tsumagari K, Kandil E. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. *J Surg Res*. 2016. 15;203(2):407-15
35. Moore RF, Sholl AB, Kidd L, Al-Qurayshi Z, Tsumagari K, Emejulu OM, Kholmatov R, Friedlander P, **Abd Elmageed ZY**, Kandil E. Metadherin Expression is Associated with Extrathyroidal Extension in Papillary Thyroid Cancer Patients. *Ann Surg Oncol*. 2016 Sep; 23 (9):2883-8.
36. Katz EG, Moustafa AA, Heidenberg D, Haney N, Peak T, Lasker GF, Knoedler M, Rittenberg D, Rezk BM, **Abd Elmageed ZY**, Yafi FA, Sikka S, Abdel-Mageed AB, Hellstrom WJ. Pioglitazone Enhances Survival and Regeneration of Pelvic Ganglion Neurons After Cavernosal Nerve Injury. *Urology*. 2016 Jan 6. pii: S0090-4295(15)01165-6.
37. Elzamly S, Elbalshy A, Abubashim M, Saad E, Agina HA, **Abd Elmageed ZY\***. Integration of VEGF and  $\alpha$ -SMA expression improves the prediction accuracy of fibrosis in chronic Hepatitis C liver biopsy. *Appl Immunohistochem & Mol Morphol*. 2017 Apr; 25(4):261-270.
38. Yang Y, Jia D, Kim H, **Abd Elmageed ZY**, Datta A, Davis R, Srivastav S, Moroz K, Crawford B, Moparty K, Thomas R, Hudson RS, Ambs S, Abdel-Mageed AB. Dysregulation of microRNA-212 Promotes Castration Resistance via hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer. *Clin Cancer Res*. 2016 Apr 1;22(7):1744-56.
39. Tsumagari K, **Abd Elmageed ZY**, Sholl AB, Friedlander P, Abdraboha M, Xing M, Boulares AH, Kandil E. Simultaneous Suppression of the MAP kinase and NF $\kappa$ B pathways Provide a Robust Therapeutic Potential for Thyroid Cancer. *Cancer letter*, 2015. 368: 46–53
40. El-Khattouti A, Selimovic D, Hannig M, Taylor EB, **Abd Elmageed ZY**, Hassan SY, Haikel Y, Kandil E, Leverkus M, Brodell RT, Megahed M, Hassan M. Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF- $\kappa$ B inhibition. *J Cellular Mol Med*. J Cell Mol Med, 2015. 20(2):266-86.
41. Laurent L, Abdel-Mageed AB, Adelson D, Arango J, Balaj L, Breakefield X, Carlson E, Carter BS, Cavaller BM, Chen CC, Cocucci E, Das S, **Abd Elmageed ZY**, Enderle D, Ezrin A, Ferrer M, Freedman J, Galas D, Gandhi R, Huentelman MJ, Jensen K, Kalani Y, Kim Y, Krichevsky AM, Lai C, Lal-Nag M, Laurent CD, Leonardo, Feng Li, Ivana Malenica, Debasis Mondal, Parham Nejad, Tushar Patel, Robert Raffai, Renee Rubio T, Skog J, Spetzler R, Tanriverdi K, Vickers K, Wang L, We Z, Weiner HL, Wong D, Yan I, Yeri A & Gould S. Meeting report: Discussions and preliminary findings on Extracellular RNA measurement methods of laboratories in the NIH Extracellular RNA Communication Consortium. *J Extracell Vesicles*. 2015 Aug; 4: 26533
42. Gokce A, **Abd Elmageed ZY**, Lasker GF, Bouljihad M, Braun SE, Kim H, Kadowitz PJ, Abdel-Mageed AB, Sikka SC, Hellstrom WJ. Intratumoral Injection of Genetically Modified Adipose Tissue-Derived Stem Cells with Human

- Interferon  $\alpha$ -2b for Treatment of Erectile Dysfunction in a Rat Model of Tunica Albuginea Fibrosis. *J Sex Med*. 2015. 12(7):1533-44.
43. Sangkum P, Gokce A, Tan RB, Bouljihad M, Kim H, Mandava SH, Saleem SN, Lasker GF, Yafi FA, **Abd Elmageed ZY**, Moparty K, Sikka SC, Abdel-Mageed AB, Hellstrom WJ. TGF- $\beta$ 1 induced urethral fibrosis in a rat model. *J Urol*. 2015. pii: S0022-5347(15)00253-0.
  44. Datta A, Bhasin N, Kim H, Ranjan M, Rider B, **Abd Elmageed ZY**, Mondal D, Agrawal KC, Abdel-Mageed AB. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells. *Cancer Lett*. 2015. 28; 362 (1):25-35.
  45. Kim H, Tarhuni A, **Abd Elmageed ZY**, Boulares AH. Poly(ADP-ribose) polymerase as a novel regulator of 17 $\beta$ -estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis. *J Transl Med*. 2015. 17; 13 (1):233.
  46. Handra-Luca A, **Abd Elmageed ZY**, Magkou C, Lae M. Immunophenotype heterogeneity in nasal glomangiopericytoma. *Case Reports in Otolaryngology*. 2015. Article ID 308743.
  47. Bhatia P, Friedlander P, **Abd Elmageed ZY**, Kandil E. Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. *Ann Transl Med*. 2015. 3(2):24-30.
  48. Bhatia P, **Abd Elmageed ZY**, Friedlander P, Aslam R, Kandil E. The utility of molecular markers in pre-operative assessment of thyroid nodules. *Future Oncol*. 2015 Aug;11(16):2343-50.
  49. **Abd Elmageed ZY**, Yang Y, Thomas R, Mondal D, Moparty K, Moroz K, Sartor O, Abdel-Mageed AB. Neoplastic Reprogramming of Patient-Derived Adipose Stem Cells by Prostate Cancer Cell Associated Exosomes. *Stem Cells*, 2014, 32(4):983-97.
  50. Kruger S, **Abd Elmageed ZY**, Hawke DH, Jansen D, Dupin CL, Chaffin AE, Abdel-Mageed AB, Alt EU, Izadpanah R. Molecular Characterization of Exosomes Released from Two Breast Cancer Cell Lines. *BMC Cancer*, 2014, 14(1):44.
  51. Kim H, **Abd Elmageed ZY\***, Davis C, El-Bahrawy AH, Naura AS, Ekaidi I, Abdel-Mageed AB, Boulares AH. Correlation between PDZK1, Cdc37, Akt and breast cancer malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37. *Mol Med*. 2014, 14;20(1):270-9 (\*Co-first author)
  52. Mathur A, **Abd Elmageed ZY**, Liu X, Kostochka ML, Zhang H, Abdel-Mageed AB, Mondal D. Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells. *PLoS One*. 2014, 4; 9 (8):e103109.
  53. Bhatia P, Tsumagari K, **Abd Elmageed ZY**, Friedlander P, Buell JF, Kandil E. Stem cell biology in thyroid cancer: Insights for novel therapies. *World J Stem Cells* 2014; 6(5): 614-619.
  54. Mohamed AA, Soliman H, Ismail M, Ziada D, Farid TM, Aref AM, Al Daly ME, **Abd Elmageed ZY**. Evaluation of circulating ADH and MIC-1 as diagnostic markers in Egyptian patients with pancreatic cancer. *Pancreatology*. 2014 pii: S1424-3903(14)01004-7.
  55. Handra-Luca A, **Abd Elmageed ZY**, Gouhier P. CD99 Expression in nasal lobular capillary hemangioma. *Histopathology*. 2014, 65(4): 583-5.
  56. Gokce A, **Abd Elmageed ZY**, Lasker GF, Mandava SH, Trost LW, Kadowitz PJ, Abdel-Mageed AB, Sikka SC, Hellstrom WJ. Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease. *Andrology*. 2014, 2(2):244-51.
  57. Kim H, **Abd Elmageed ZY\***, Ju J, Naura AS, Abdel-Mageed AB, Varughese S, Paul D, Alahari S, Catling A, Kim JG, Boulares AH. PDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growth. *Mol Med*. 2013 Jun 26. 19: 253-62 (\*Co-first Author)
  58. **Abd Elmageed ZY**, Moroz K, Kandil E. Clinical significance of CD146 and latexin during different stages of thyroid cancer. *Mol Cell Biochem*. 2013 Sep; 381(1-2): 95-103.

59. **Abd Elmageed ZY**, Moroz K, Srivastav S, Crawford B, Moparty K, Thomas R, Abdel-Mageed AB. The importance of Estrogen-ER-beta axis in health disparity of Prostate Cancer. *Carcinogenesis* 2013. 34 (9): 2017-23.
60. Naura AS, Kim H, Ju J, Rodriguez PC, Jordan J, Catling AD, Rezk BM, **Abd Elmageed ZY**, Pyakurel K, Tarhuni AF, Abughazleh MQ, Errami Y, Zerfaoui M, Ochoa AO, Boulares AH. Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-NF- $\kappa$ B-GATA-3-IL-4 axis without a prominent effect on PARP. *J Biol Chem*. 2013 Jan 18; 288 (3): 1458-68.
61. Nada AS, Hawas AM, **Abd Elmageed ZY**, Amin NE. Protective value of *Aloe vera* extract against  $\gamma$ -irradiation induced some biochemical disorders in rats. *J. Rad. Res Appl. Sci*. 2013. 6: 31-37.
62. Kandil E, Tsumagari K, Ma J, **Abd Elmageed ZY**, Slakey DP, Mondal D, Abdel-Mageed AB. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways". *J. Surg. Res*. 2013. 184 (2): 898-906.
63. Gur S, Sikka SC, Abdel-Mageed AB, **Abd Elmageed ZY**, Rezk B, Pankey E, Kadowitz PJ, Hellstrom WJ. Imatinib Mesylate (Gleevec) Induces Human Corpus Cavernosum Relaxation by Inhibiting Receptor Tyrosine Kinases (RTKs): Identification of New RTK Targets. *Urology*. 2013. 82 (3): 745.e11-6.
64. **Abd Elmageed ZY**, Naura AS, Errami Y, Zerfaoui M. The Poly(ADP-ribose) polymerases (PARPs): New roles in intracellular transport. *Cell Signal*. 2012 Jan; 24(1):1-8. Epub 2011 Aug 5.
65. Nada AS, Hawas AM, Amin NE, Elnashar MM, **Abd Elmageed ZY\***. Radioprotective Effect of Curcuma longa Extract on  $\gamma$ -Irradiation-induced Oxidative Stress in Rats. *Can J Physiol Pharmacol*. 2012 Apr; 90 (4): 415-23.
66. Mohammad MA, Zeeneldin AA, **Abd Elmageed ZY**, Khalil EK, Mahdy SM, Sharada HM, Sharawy SK, Abdel-Wahab AA. Clinical Relevance of Cyclooxygenase-2 and Matrix Metalloproteinases (MMP-2 and MT1-MMP) in Human Breast Cancer Tissue. *Mol Cell Biochem*. 2012 Jul; 366 (1-2): 269-75.
67. Abdel-Khalek M, **Abd Elmageed Z**, Khan A, Broussard G, Kandil E. Cholestatic hepatitis in a patient with Graves' disease resolved with total thyroidectomy. *Trop. Gastroenterol*. 2011; 32 (4): 328–330.
68. Matrougui K, **Abd Elmageed Z**, Kassan M, Choi S, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Kadowitz P, Belmadani S, Partyka M. Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. *Am J Pathol*. 2011 Jan; 178 (1): 434-41.
69. Kandil E, Khalek MA, Thethi T, **Abd Elmageed Z**, Khan A, Jaffe BM. Thyroid storm in a patient with fulminant hepatic failure. *Laryngoscope*. 2011 Jan; 121 (1): 164-6.
70. Amin AH, **Abd Elmageed ZY**, Partyka M, Matrougui K. Mechanisms of myogenic tone of coronary arteriole: Role of downstream signaling of the EGFR tyrosine kinase. *Microvasc Res*. 2011. 81 (1): 135-42.
71. Ju J, Naura AS, Errami Y, Zerfaoui M, Kim H, Kim JG, **Abd Elmageed ZY**, Abdel-Mageed AB, Giardina C, Beg AA, Smulson ME, Boulares AH. Phosphorylation of p50 NF-kappaB at a single serine residue by DNA-dependent protein kinase is critical for VCAM-1 expression upon TNF treatment. *J Biol Chem*. 2010. 285 (52): 41152-60.
72. Naura AS, Zerfaoui M, Kim H, **Abd Elmageed ZY**, Rodriguez PC, Hans CP, Ju J, Errami Y, Park J, Ochoa AC, Boulares AH. Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation. *J Immunol*. 2010. 185(5):3076-85.
73. Zerfaoui M, Errami Y, Naura AS, Suzuki Y, Kim H, Ju J, Liu T, Hans CP, Kim JG, **Abd Elmageed ZY**, Koochekpour S, Catling A, Boulares AH. Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. *J Immunol*. 2010. 185 (3):1894-902.
74. Amin AH, **Abd Elmageed ZY**, Nair D, Partyka MI, Kadowitz PJ, Belmadani S, Matrougui K. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic mice. *Lab Invest*. 2010. 90 (7): 985-96.
75. **Abd Elmageed ZY**, Gaur RL, Williams M, Abdraboh ME, Rao PN, Raj MH, Ismail FM, Ouhtit A. Characterization of Coordinated Immediate Responses by p16(INK4A) and p53 Pathways in UVB-Irradiated Human Skin Cells. *J Invest Dermatol*. 2009. 129(1):175-83.

76. Shaarawy SM, Tohamy AA, Elgendy SM, **Elmageed ZY**, Bahnasy A, Mohamed MS, Kandil E, Matrougui K. Protective effects of garlic and silymarin on NDEA-induced rat's hepatotoxicity. *Int J Biol Sci*. 2009. 5(6): 549-57.
77. Ouhtit A, Gaur GL, **Abd Elmageed ZY**, Fernando A, Thouta R, Trappey AK, Abdraboh ME, El-Sayyad HA; Rao PN; Raj MH. Towards understanding the mode of action of the multifaceted cell adhesion receptor CD146. *Biochim Biophys Acta*. 2009. 1795(2): 130-6.
78. Johnson T, Ouhtit A, Gaur R, Fernando A, Schwarzenberger P, Su J, Ismail MF, El-Sayyad HI, Karande A, **Elmageed ZA**, Rao P, Raj M. Riboflavin carrier protein (RCP) is a tumor marker of prostate cancer. *Front Biosci*. 2009. 14:3634-40.
79. Raj M, **Abd Elmageed ZY**, Zhou J, Nguyen L, Azam GA, Prakash NR, and Allal Ouhtit. Synergistic Inhibition of Survivin Expression and Proliferation of SKOV3 Ovarian Cancer Cells by Indole-3-Carbinol and Resveratrol. *Gynecol Oncol*. 2008. 110 (3):432-8.
80. Ouhtit A, **Abd Elmageed ZY**, Abdraboh ME, Lioe TF, Raj MH. *In vivo* evidence for the role of CD44s in promoting breast cancer metastasis to the liver. *Am J Pathol*. 2007. 171(6): 2033-9.

### Conferences and Abstracts (77 conference and poster presentations)

1. Dawud D, Rahman S, Hernandez AS, McLane K, Michalak K, Stephen DJ, **Abd Elmageed ZY**. Novel transmembrane and tetratricopeptide repeat containing-4 protein as a prospective marker in breast cancer. 2022 Via Research Recognition Day, VCOM Virginia. Feb. 25, 2022
2. Hernandez AS, Hassan D, **Abd Elmageed ZY**. Transmembrane and Tetratricopeptide Repeat Containing isoforms as novel biomarkers for diagnosis of prostate cancer. Sixth annual Edward Via College of Osteopathic Medicine Via Research Recognition Day on the VCOM-Carolinas Campus. March 19, 2021.
3. Exosome transfer of miR-6068 mediates the aggressive phenotypes of prostate cancer. Mohamed S. A. Gaballah, Shahenda Mahgoub, Mitra Joshaghani, Hamdy E. Ali, Tamer Fandy, Hamed I. Ali, Zeinab A. Hassan, **Zakaria Y. Abd Elmageed**. American Association of Pharmaceutical Sciences. AAPS PharmaSci 360. October 26-November 5, 2020.
4. TMTC4 is a Novel Biomarker and Potential Therapeutic Target in Prostate Cancer. Mitra Joshaghani, Hamdy Ali, Mohamed Gaballah, Mohamed Haque, Hamed I. Ali, George Udeani, Tamer Fandy, Enrique E. Arredondo, **Zakaria Y. Abd Elmageed**. American Association of Pharmaceutical Sciences. AAPS PharmaSci 360. October 26-November 5, 2020.
5. Gaballa RR, Mahmoud MO, Ali H, Fandy T, Ali HI, Salem HF, Kandeil MA, **Abd Elmageed ZY**. Exosomal transfer of ITG2A protein promotes aggressive behavior of prostate cancer cells derived from local tumors by increasing their metastatic abilities. American Association of Pharmaceutical Scientists 2019 PharmSci-360 meeting in San Antonio, Texas, November 3-6, 2019
6. Gaballah MS, Mahgoub S, Fandy T, Ali HE, Ali HI, Hassan Z, **Abd Elmageed ZY**. Exosomes-associated miR-7704, miR-6068 and miR-6076 as novel diagnostic and prognostic biomarkers in prostate cancer patients. American Association of Pharmaceutical Scientists 2019 PharmSci-360 meeting in San Antonio, Texas, from November 3-6, 2019
7. Gaballa RR, Ali H, Gaballah M, Fandy T, Ali HI, **Abd Elmageed ZY**. Overexpression of novel TMTC4 promotes migration and invasion of breast cancer cells. American Association of Pharmaceutical Scientists 2019 PharmSci-360 meeting in San Antonio, Texas, from November 3-6, 2019
8. Ali HEA, Gaballa R, Gaballah M, Ali HI, Bustamante J, **Abd Elmageed ZY**. The role of exosomes-associated microRNAs in prostate cancer disparity and their association with tumor aggressiveness. Research Symposium on Health disparities: Community Engagement. University of Texas Rio Grande Valley, School of Medicine, Edinburg, Texas. September 13-14, 2019

9. **Abd Elmageed, ZY**, Gaballah M, Palakurthi S, Gomer R. Exosomes as a mechanistic model for developing drug resistance in prostate cancer patients. President Excellence Fund Symposium. Texas A&M University. April 4, 2019. College Station, Texas.
10. Ali HEA, Gaballa R, Sholl AS, Gaballah M, Bustamante J, Zanwar P, Ali HI, **Abd Elmageed ZY**. Exosomal microRNAs are associated with prostate cancer aggressiveness in African American patients. The 11<sup>th</sup> AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. AACR meeting November 2-5, 2018, New Orleans, LA.
11. Gaballa R, Gaballah M, Ali HEA, Sholl AS, Ali HI, **Abd Elmageed ZY**. Exosomes-associated miR-5001, miR-3692 and miR-4529 are novel biomarkers for aggressive prostate cancer and associated with poor prognosis in African American patients. The 11<sup>th</sup> AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. AACR meeting in November 2-5, 2018, New Orleans, LA.
12. Hamdy E.A. Ali, Andrew S. Sholl, Pei-Yau Lung, Juan Bustamante, Jinfeng Zhang, King S. Coffield, **Abd Elmageed, ZY**. Exosomes-associated miR-3128 and miR-3613 are dysregulated in African American men with prostate cancer and correlated with poor prognosis. The 10<sup>th</sup> AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. AACR meeting September 25-28, 2017, Atlanta, Georgia.
13. Hamdy E.A. Ali, Pei-Yau Lung, Shaimaa Gad, Andrew S. Sholl, Hamed I. Ali, Jinfeng Zhang, **Abd Elmageed, ZY**. Transcriptome-wide profiling identifies novel differential genes associated with health disparity of prostate cancer. The 10<sup>th</sup> AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. AACR meeting September 25-28, 2017, Atlanta, Georgia.
14. Shaimaa A. Gad, Hamdy EA Ali, Hamed Ismail-Aly, **Abd Elmageed, ZY**. Exosomal microRNAs as a novel mechanism of resistance to BRAF-V600E inhibitor in melanoma cells. Innovations in Cancer Prevention and Research Conference. Cancer Prevention & research Institute of Texas. November 13-14, 2017. Austin, Texas
15. Hamdy E.A. Ali, Shaimaa Gad, Andrew B. Sholl, Hamed I. Ali, **Abd Elmageed, ZY**. Ornithine aminotransferase (OAT) and Adenosylmethionine decarboxylase 1 (AMD1) as novel genes associated with health disparity of prostate cancer. Innovations in Cancer Prevention and Research Conference. Cancer Prevention & research Institute of Texas. November 13-14, 2017. Austin, Texas
16. Shaimaa A. Gad, Hamdy EA Ali, Hamed Ismail-Aly, **Abd Elmageed, ZY**. The role of exosomes-associated microRNAs in developing drug resistance in melanoma. The 4th Annual Texas A&M University ENG-LIFE Workshop "Biomanufacturing and synthetic Biology". April 14, 2017. College Station, TX
17. Moustafa A, Ali H, Sholl AB, Tsumagari K, Abdel-Mageed AB, **Abd Elmageed ZY**. New insights into the role of exosomes-associated onco-microRNAs in African Americans with prostate cancer. Professional Development Meeting, 2016. NIH Center to Reduce Cancer Health Disparity, Bethesda, MD. April 23-24, 2016.
18. Moustafa A, Sholl AB, Tsumagari K, Hassan M, Kandil E, Abdel-Mageed AB **Abd Elmageed ZY**. Differential expression of exosomes-associated onco-microRNAs in African Americans with prostate cancer. The American Association for Cancer Research (AACR) Annual Meeting 2016. New Orleans, LA. April 15-20, 2016.
19. **Abd Elmageed ZY**, Tsumagari K, Sholl AB, Miccoli P, Kandil E. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E in 130 samples of papillary thyroid cancer patients. The American Association of Endocrine Cancer. Baltimore, MD. April 10-12, 2016.
20. Moore R, Tsumagari K, Sholl AB, L Kidd, Al-Qurashi Z, **Abd Elmageed ZY**, Kandil E. Metadherin expression in papillary thyroid cancer. The American Association of Endocrine Cancer. Baltimore, MD. April 10-12, 2016.

21. Tsumagari K, **Abd Elmageed, ZY**, Sholl AB, Bhatia P, Deniwar A, Kandil E. Combination of MEK and proteasome inhibitor synergistically induces cell cycle arrest and the inhibition of cell growth and migration. *Journal of the American College of Surgeons*. 2016: 221 (4) Supplement 4, page e78.
22. Kassab S, Bedewy W, Malky WH, Gouda AM, **Abd Elmageed ZY**, Al-Rousan R, Abdalla A, Ali HI. Design, Synthesis, In Silico Study, and Biological Screening of Flavin Analogues as Novel Selective and Potent Antitumor Agents. Research Colloquium, Texas A&M University, Health Science Center, Irma Lerma Rangel, College of Pharmacy, 2016, Jun. 2-3.
23. Ali J, Bedewy W, Malky WH, Gouda AM, **Abd Elmageed ZY**, Al-Rousan R, Abdalla A, Ali HI. Design, Synthesis, In Silico Study, and Biological Screening of Flavin Analogues as Novel Selective and Potent Antitumor Agents. 43rd Annual MALTO Conference for the Medicinal Chemistry, in Houston University, May 23-24, 2016
24. Ranjan M, **Abd Elmageed ZY**, Kim H, Datta A, Bhasin N, Braun SB, Mondal D, Abdel-Mageed AB. Stem-cell based selective delivery of alpha keto reductases for therapeutic targeting of residual androgens in prostate cancer. *Cancer Research*. Abstract 3537. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA
25. Gokce A, Lasker GF, **Abd Elmageed ZY**, Mandava SH, Hagan S, Bouljihad M, Kadowitz P, Abdel-Mageed AB, Sikka S, Hellstrom WJ. Early combined treatment with avanafil and adipose tissue-derived stem cells promotes recovery of erectile function in a rat model of post-prostatectomy induced erectile dysfunction. *European Urology Supplements*. 04/2015; 14(2). DOI: 10.1016/S1569-9056(15)60049-5.
26. Gupta I, Ouhtit A, Fernando A, **Abd Elmageed Z**, Shanmuganathan S. CD146/Akt/NF-kappa-B/Latexin, a novel pathway suppressing breast tumor growth. *Annals of Oncology*. 05/2015; 26 (suppl 3). DOI: 10.1093/annonc/mdv121.05
27. Rezk B, Moustafa AA, Sangkum P, **Abd Elmageed ZY**, Sikka S, Abdel-Mageed AB, Hellstrom WJG. Differential effects of Sildenafil and Tadalafil on human penile smooth muscle cells: new insights for old mechanisms. 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA). Miami, FL, November 20 - 23, 2014.
28. Katz E, Rezk B, Haney NM, Heidelberg D, Lasker G, **Abd Elmageed ZY**, Abdel-Mageed AB, Hellstrom WJG. Pioglitazone enhances survival and regeneration of pelvic ganglia neurons after cavernosal nerve crush in the rat. 20th Annual Fall Scientific Meeting of SMSNA. Miami, FL, November 20 - 23, 2014.
29. Handra-Luca A, **Abd Elmageed ZY**, Gouhier P. Immunophenotype heterogeneity in nasal glomangiopericytoma. 26<sup>th</sup> European Congress of Pathology. August 30 to September 3<sup>rd</sup>, 2014. ExCeL, London, UK.
30. **Abd Elmageed ZY**, Lal-Nag M, Saleem S, Mondal D, Thomas R, Ferrer M, Abdel-Mageed, AB. Targeting Tumor-Derived exRNA-Containing Exosomes by High Throughput Screening. NIH Extracellular RNA Communication Program. 2<sup>nd</sup> Investigators' Meeting. National Center for Advancing Translational Sciences (NCATS), Bethesda North Marriot, Bethesda, MD. May 19-20, 2014.
31. Moustafa A.A., Taha H, Abdel-Mageed AB, **Abd Elmageed ZY**. Discovering the role of putative microRNAs in prostate tumorigenesis. 25<sup>th</sup> Annual Health Sciences Research Day held on April 2-3, 2014, Tulane University School of Medicine, New Orleans, LA.
32. **Abd Elmageed ZY**, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K, Fang Z, Rezk BM, Moparty K, Sikka SC, Sartor O, Abdel-Mageed AB. Neoplastic Reprogramming of Patient Derived Adipose Stem Cells by Prostate Cancer Cell-Associated Exosomes. Louisiana Cancer Research Consortium (LCRC) Retreat. New Orleans, LA. March 28, 2014.

33. Kim H, **Abd Elmageed ZY**, Datta A, Abdel-Mageed AB. 17 $\beta$ -Estradiol-ER $\beta$  Axis Confers Proliferation and Migration through IGF-1R-Dependent Expression of TMPRSS2 in Castration-Resistant PC-3 Cells. AACR annual meeting. April 6-10, 2014. San Diego CA. Cited in: Cancer Research 10/2014; 74(19 Supplement):3313-3313.
34. **Abd Elmageed ZY**, Yang Y, Thomas R, Ranjan M, Monda D, Moroz K, Fang Z, Rezk BM, Moparty K, Sikka SC, Sartor O, Abdel-Mageed AB. Neoplastic Reprogramming of Patient Derived Adipose Stem Cells by Prostate Cancer Cell-Associated Exosomes. Louisiana Cancer Research Consortium (LCRC) Retreat. New Orleans, LA. March 28, 2014.
35. Datta A, Rider B, **Abd Elmageed ZY**, Kim H, Mondal D, Abdel-Mageed AB. A Synthetic Flavonoids Abrogates Doxorubicin Resistance through Inhibition of Focal Adhesion Kinase and P-glycoprotein Activity in Breast cancer Cells. Louisiana Cancer Research Consortium (LCRC) Retreat. New Orleans, LA. March 28, 2014.
36. Ranjan M, Naga MK, **Abd Elmageed ZY**, Braun SE, Mondal D, Abdel Mageed AB. Stem Cell-Based Selective Delivery of Alpha Keto Reductases for Therapeutic Targeting of residual Androgens in Metastatic Prostate Cancer. Louisiana Cancer Research Consortium (LCRC) Retreat. New Orleans, LA. March 28, 2014.
37. Bhasin N, **Abd Elmageed ZY**, Kim H, Ranjan M, Alzoubi M, Moroz K, Abdel-Mageed AB. Selective Membrane Expression of DAD1 is Associated with Survival of Prostate Cancer Cells. Louisiana Cancer Research Consortium (LCRC) Retreat. New Orleans, LA. March 28, 2014.
38. Davis C, Kim H, **Abd Elmageed ZY**, Naura A, Abdel-Mageed AB, Boulares H. Correlation between PDZK1, Cdc37 and Breast Cancer Malignancy: The Role of PDZK1 in Growth through Akt Stabilization by Increasing and Interacting with Cdc37. Louisiana Cancer Research Consortium (LCRC) Retreat. New Orleans, LA. March 28, 2014.
39. **Abd Elmageed ZY**, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz M, Rezk B, Moparty K, Abdel-Mageed AB. Stem cell-based therapy: A double-edged sword? The 9<sup>th</sup> Int. Conference on Anticancer Research. Sithonia, Greece, October 6-10, 2014. Anticancer Research, 2014, 34(10): 5791.
40. **Abd Elmageed ZY**, Kim H, Thomas R, Moparty K, Abdel-Mageed AB. Estradiol-ER $\beta$  signaling axis in disparity of prostate cancer in African American men. 6<sup>th</sup> AACR Conference on the science of cancer health disparities. December 6-9, 2013. Atlanta, GA.
41. Gokce A, **Abd Elmageed ZY**, Lasker GF, Kim H, Sikka S, Kadowitz P, Abdel-Mageed AB, Hellstrom WJ. Early combined treatment with Avanafil and adipose tissue-derived stem cells promotes recovery of erectile function in a rat model of postprostatectomy induced erectile dysfunction. 19<sup>th</sup> Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA). Nov 21- 24, 2013. New Orleans, LA.
42. Gokce A, Lasker GF, **Abd Elmageed ZY**, Mandava SH, Hagan S, Bouljihad M, Kadowitz PJ, Abdel-Mageed Ab, Sikka SC. Hellstrom WJ. Early combined treatment with Avanafil and adipose tissue-derived stem cells promote recovery of erectile function in a rat model of postprostatectomy induced erectile dysfunction. Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA). Nov 21- 24, 2013. New Orleans, LA.
43. Rezk BM, **Abd Elmageed ZY**, Gur S, Gokce A, Taha H, Khedr ME, Sikka S, Abdel-Mageed AB, Hellstrom WJ. A Potent Antioxidant 4-hydroxy-2,5,6-triaminopyrimidine (HTP) Relaxes Cavernosal Smooth Muscle and is a Potential Therapeutic Agent for Erectile Dysfunction. 19<sup>th</sup> Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA). Nov 21- 24, 2013. New Orleans, LA.
44. Taha H, Abdel-Mageed AB, **Abd Elmageed ZY**. Discovering the role of putative microRNAs in prostate tumorigenesis. Louisiana Clinical and Translational Sciences (LA-CATs) Research Day held on Sept. 16, 2013, LSU Health Science Center, New Orleans, LA.

45. **Abd Elmageed ZY**, Yang Y, Thomas R, Ranjan M, Monda D, Moro K, Fang Z, Rezk BM, Moparty K, Sikka SC, Sartor O, Abdel-Mageed AB. Neoplastic Transformation of Patient Derived Adipose Stem Cells Induced by Prostate Cancer Cell-Associated Microvesicles. AACR annual meeting. April 6-10, 2013. Washington, DC.
46. **Abd Elmageed ZY**, Yang Y, Moparty K, Thomas R, Sikka SC, Abdel-Mageed AB. Potential role of stem cells-derived androgen in prostate cancer growth and metastasis. The 10th International Congress of Andrology, 23 – 26 February 2013, Melbourne, Australia. Abstract published in *Andrology*, 1 (S1): 44–114, March 2013.
47. Gokce A, **Abd Elmageed ZY**, Lasker G, Mandava SH, Trost L, Kadowitz P, Abdel-Mageed A, Sikka S, Hellstrom WJ. Intratunical injection of adipose tissue-derived stem cells in combination with human interferon  $\alpha$ -2b gene therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronies disease. American Urology Association (AUA). May 4-8, 2013. San Diego, CA. Published in *The Journal of Urology* vol. 189, 2013. p. e683
48. Gokce A., Lasker G, Mandava SH, **Abd Elmageed ZY**, Trost L, Kadowitz P, Hellstrom W. Long-term continuous treatment with Avanafil promotes recovery of erectile function in a rat model of postprostatectomy induced erectile dysfunction. *The Journal of Urology*, 2013. 189(4), e333.
49. Bhasin N, Ranjan M, Alzoubi M, **Abd Elmageed ZY**, Abdel-Mageed AB. Selective Expression of VPS45 in Plasma Membrane is Associated with Survival of Prostate Cancer Cells. LCRC Retreat. New Orleans, LA. March 8, 2013.
50. Ranjan M, Bhasin N, Alzoubi M, **Abd Elmageed ZY**, Mondal D, Abdel Mageed AB. Stem Cell-Based Selective Delivery of  $\alpha$ -HSD to Metastatic Prostate Cancer: Implications for Targeting Residual Androgens in African Americans with CRPC. LCRC Retreat. New Orleans, LA. March 8, 2013.
51. **Abd Elmageed ZY**, Yao L, Moroz K, Kandil E. CD146-Latexin crosstalk and their potential role in thyroid tumorigenesis". Academic Surgical Congress meeting. New Orleans, LA, February 4-7<sup>th</sup>, 2013.
52. Gokce A, **Abd Elmageed ZY**, Lasker G, Mandava H, Trost L, Kadowitz P, Hellstrom W. (2013, May). Adipose Tissue-Derived Stem Cell Therapy for Prevention and Treatment of Erectile Dysfunction In a Rat Model of Peyronie's Disease. In *Andrology* (Vol. 1, pp. 94-94). 111 River St, Hoboken 07030-5774, NJ USA: Wiley-Blackwell.
53. Li X, **Abd Elmageed ZY**, Kandil E. Simultaneous suppression of the MAP kinase and PI3K/Akt pathways in aggressive thyroid cancer. Academic Surgical Congress meeting. New Orleans, LA, February 4-7<sup>th</sup>, 2013.
54. Mandava SH, **Abd Elmageed ZY**, Lasker G, Gokce A, Trost L, Kadowitz P, Sikka, S (2013, May). Botulinum Toxin Results In Decreased Proliferation And Apoptosis In The Rat Bulbous Spongiosum. In *Andrology* (Vol. 1, pp. 75-75). 111 River St, Hoboken 07030-5774, NJ USA: Wiley-Blackwell.
55. Rezk BM, **Abd Elmageed ZY**, Serefoglu EC, Gur S, Khedr MEY, Mageed ABA. 4-Hydroxy-2, 5, 6-Triaminopyrimidine Enhances Expression of Mitochondrial Antioxidant Superoxide Dismutase in Human Corpora Cavernosa Cells. SFRBM's 19th Annual Meeting, San Diego, November, 2012.
56. Ma J, **Abd Elmageed ZY**, Li X, Abdel-Mageed AB, Mondal D, Kandil E. Simultaneous suppression of the MAP kinase and PI3K/Akt pathways by AZD-6244 and GDC-0941 synergistically inhibits thyroid cancer cells. LCRC Retreat. Xavier University, New Orleans, LA. March 10-11<sup>th</sup>, 2012.
57. Jia D, Yang Y., **Abd Elmageed ZY**, Davis R., Moparty K, Thomas R, Abdel-Mageed AB (2012, February). Selective ARE and AR Binding by hnRNPH1: Implications for Racial Disparity of Prostate Cancer. In *Cellular Oncology* (vol. 35, pp. s16-s16). Van Godewijkstraat 30, 3311 GZ Dordrecht, Netherlands: Springer.
58. Chandra S, Rezk B, **Abd Elmageed ZY**, Mandava S, Abdel-Mageed AB, Hellstrom, W, Sikka S. Differential cytokine expression in leukospermic and nonleukospermic subjects as a novel tool to predict treatment response. American Association of Andrology meeting. Tucson, Arizona. 37<sup>th</sup> Annual meeting, 2012.

59. **Abd Elmageed ZY**, Moroz K, Srivastav S, Abdel-Mageed AB, Kandil E. The role of Cell adhesion molecule CD146 and its downstream signaling gene in mediating thyroid tumor progression. American Association of Endocrine Surgery annual meeting. Huston, Texas, April 11-13<sup>th</sup>, 2011.
60. **Abd Elmageed ZY**, Yang Y., Thomas R., Mondal D., Moparty K., Moroz K., Sartor O., Abdel-Mageed A.B. Prostate Cancer Cells Confer Neoplastic Transformation and Androgen Production by Patient Adipose Tissue-Derived Stem Cells. LCRC Retreat. Xavier University, New Orleans, LA. March 10-11<sup>th</sup>, 2012.
61. **Abd Elmageed ZY**, Moroz K, Thomas R, Moparty K, Abdel-Mageed AB. The importance of Estrogen-ER beta axis in racial disparity of prostate cancer. AACR annual meeting from March 31 to April 4<sup>th</sup>, 2012. Chicago, IL.
62. **Abd Elmageed ZY**, Abbruscato F, Abdel-Mageed AB, Kandil E. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MAPK pathway inhibitor AZD-6244 and genetic-potentiated synergism with the PIK3 inhibitor GDC-0941. American Association of Endocrine Surgery annual meeting. Huston, Texas, April 11-13<sup>th</sup>, 2011.
63. **Abd Elmageed ZY**, Moroz K, Srivastav S, Crawford B, Moparty K, Thomas R., Abdel-Mageed AB. Activation of Androgen Receptor by Estrogen-ER $\beta$  Axis in Prostate Cancer Cells: Potential Role in Racial Disparity of Prostate Cancer. LCRC Retreat. Xavier University, New Orleans, LA. April 8-9<sup>th</sup>, 2011.
64. Kim H, Ju J, Naura AS, **Abd Elmageed ZY**, Rezk BM, Abdel-Mageed AB, Catling A, Kim J, Boulares H. PDZK1 expression is age-phasic in human breast cancer and a growth-promoting factor that is indirectly regulated by estrogen through IGF-1R. Experimental Biology Meeting, April 9-13, Washington DC, 2011.
65. Rezk BM, Khanna M, Dewitt S, **Abd Elmageed ZY**, Abdel-Mageed AB and Sikka SC. Homocysteine Reduces Sperm Motility via Elevation of Mitochondrial Superoxide Anions in Normal and Subfertile subjects: Potential Effect of Co-treatment with Folic acid. *Free Radic Biol Med* 49: S195 (2010).
66. Amin A, **Abd Elmageed ZY**, Partyka M, Belmadani S and Matrougui K. Injected stimulated Multipotent Stromal cell with EGF enhances ischemia-induced vasculogenesis in type 2 diabetes. Southern Regional Meeting at-a-Glance Hotel Inter-Continental, New Orleans, Louisiana February 25-27, 2010.
67. **Abd Elmageed, ZY**, Alabbas HH, Kandil E, Matrougi K. The role of cell adhesion molecule CD146 and its novel downstream signaling gene latexin in mediating thyroid cancer. Thyroid Cancer Meeting, 2009. Florida, USA.
68. **Abd Elmageed ZY**, Amin AH, Nair D, Partyka M, Belmadani S, Matrougui K. The Inhibition of Poly (ADP-ribose) Polymerase-1 (PARP-1) Significantly Accelerates the Vasculogenesis in a Model of Hind Limb Ischemia (Abstract). American Heart Association. New Orleans, LA 2009. *Circulation*. 2009;120: S1052
69. **Abd Elmageed ZY**, Nair D, Gonzalez-Villalobos RA, Chentoufi AA, Partyka M, Belmadani S, Matrougui K. Natural Regulatory T Cells Control Coronary Arteriolar Endothelial Dysfunction and Hypertension in Mice. (Abstract). American Heart Association. New Orleans, LA 2009. *Circulation*. 2009; 120: S1106.
70. **Abd Elmageed ZY**, Amin A, Partyka, M, Palen, D and Matrougui K. Mechanisms of Coronary Arteriolar Myogenic Tone: Role of Down Stream Signaling to EGFR Tyrosine Kinase (Abstract). American Heart Association. New Orleans, LA 2009. *Circulation*. 2009; 120: S1161
71. **Abd Elmageed ZY**, Amin A, Partyka, M, Palen, D and Matrougui K. Differential Effects of GRB2-SOS, JNK, STAT and Akt Downstream Signaling to EGFR Tyrosine Kinase in Mice Coronary Arteriolar Myogenic Tone. Experimental Biology and Medicine Meeting April 19-23, 2009 in New Orleans, LA.
72. Madani S, Abdraboh M, **Abd Elmageed ZY**, Capps C, Ouhtit A. Identification of TGF-beta 2 as a novel CD44-downstream target gene for anti-metastatic breast cancer therapy. *The 49<sup>th</sup> Annual National Student Research Forum* in, April 24-25, 2008 in Galveston, Texas.

73. Raj MH, **Abd Elmageed ZY**, Zhou J, Nguyen L, Azam GA, Rao PN, Ouhtit A. Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells. Louisiana Cancer Research Consortium (LCRC) retreat. UNO, New Orleans, LA, 2008.
74. **Abd Elmageed ZY**, Raj M and Allal Ouhtit A. CD146-downstream signaling mechanisms mediating breast tumour invasion. The American Association for Cancer Research Annual Meeting, April 12-16, 2008 in San Diego, CA.
75. Nelson E, Abdraboh M, **Abd Elmageed ZY**, Taylor AM, Capps C, Welsh DA, Ouhtit A. Dysfunction of Mesenchymal Stem Cell-CD44 signaling in Emphysema. The 3<sup>d</sup> National Cancer Institute Forum in New York City, August 2<sup>nd</sup>, 2007.
76. **Abd Elmageed ZY**, Abdraboh M, Masoodi HM, Ouhtit A. CD146-downstream signaling mediating breast tumor invasion/metastasis. 30th Annual San Antonio Breast Cancer Symposium, December 13-16, 2007, San Antonio, Texas, USA.
77. Ouhtit A, **Abd Elmageed ZY**, Capps C., Becker T. Identification of P16-Downstream Target Genes Implicated in the Early Dysfunction of UV-Induced Cell Cycle Mechanisms and Initiation of Melanoma. *The 4<sup>th</sup> International Melanoma Congress in New York City*, November 1-4, 2007. Published in *Pigment cell Res.* 20:513-580. P157.